相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation
Shi-Suo Du et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Y. Doki et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
Zi-Xian Wang et al.
CANCER CELL (2022)
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Morihito Okada et al.
CLINICAL CANCER RESEARCH (2022)
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
Zhihao Lu et al.
BMJ-BRITISH MEDICAL JOURNAL (2022)
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
Michael Hwang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors
Yeun-Yoon Kim et al.
GASTRIC CANCER (2021)
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)
Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis
Han-Yu Deng et al.
NUTRITION (2021)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer
Miaomiao Gou et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2021)
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
Qijie Zhao et al.
FRONTIERS IN IMMUNOLOGY (2021)
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial
Huiyan Luo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong-Mu Sun et al.
LANCET (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sarcopenia and Short-Term Outcomes After Esophagectomy: A Meta-analysis
Pei-yu Wang et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang et al.
LANCET ONCOLOGY (2020)
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors
Benoit Roch et al.
LUNG CANCER (2020)
Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Han Gyul Yoon et al.
CANCERS (2020)
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer
Shani Ben Dori et al.
LUNG CANCER (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy
Aparna R. Parikh et al.
ONCOLOGIST (2019)
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
Florian R. Greten et al.
IMMUNITY (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer: a systematic review and meta-analysis
Giovanni Pirozzolo et al.
JOURNAL OF THORACIC DISEASE (2019)
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
Ludovic Fournel et al.
CANCER LETTERS (2019)
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
Shunli Peng et al.
MOLECULAR CANCER (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma
Kirtesh R. Patel et al.
ONCOIMMUNOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy
Samantha Cox et al.
RADIOTHERAPY AND ONCOLOGY (2017)
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y. Xu-Monette et al.
FRONTIERS IN IMMUNOLOGY (2017)
Muscle as a paracrine and endocrine organ
Jimena Giudice et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
Landscape of Microsatellite Instability Across 39 Cancer Types
Russell Bonneville et al.
JCO PRECISION ONCOLOGY (2017)
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1
Marisa Dolled-Filhart et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Programmed Death Ligand-1 Immunohistochemistry Friend or Foe?
Keith M. Kerr et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Exercise-stimulated interleukin-15 is controlled by AMPK and regulates skin metabolism and aging
Justin D. Crane et al.
AGING CELL (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer In what state is this art?
Keith M. Kerr et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Cancer-related inflammation and treatment effectiveness
Connie I. Diakos et al.
LANCET ONCOLOGY (2014)
Cancer cachexia: understanding the molecular basis
Josep M. Argiles et al.
NATURE REVIEWS CANCER (2014)
The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
Donald C. McMillan
CANCER TREATMENT REVIEWS (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Muscle-derived positive and negative regulators of the immune response
H Wiendl et al.
CURRENT OPINION IN RHEUMATOLOGY (2005)
Immunobiology of muscle: advances in understanding an immunological microenvironment
H Wiendl et al.
TRENDS IN IMMUNOLOGY (2005)
Microsatellites: Simple sequences with complex evolution
H Ellegren
NATURE REVIEWS GENETICS (2004)
Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies
D Figarella-Branger et al.
MUSCLE & NERVE (2003)
分享论文
